Erste Asset Management GmbH Lowers Stock Position in Edwards Lifesciences Corporation $EW

Erste Asset Management GmbH lessened its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 50.6% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 21,520 shares of the medical research company’s stock after selling 22,016 shares during the quarter. Erste Asset Management GmbH’s holdings in Edwards Lifesciences were worth $1,661,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Brighton Jones LLC purchased a new position in shares of Edwards Lifesciences in the 4th quarter valued at about $266,000. Arkadios Wealth Advisors acquired a new stake in Edwards Lifesciences in the second quarter valued at approximately $300,000. Premier Path Wealth Partners LLC increased its position in shares of Edwards Lifesciences by 10.4% in the second quarter. Premier Path Wealth Partners LLC now owns 4,210 shares of the medical research company’s stock valued at $329,000 after buying an additional 395 shares in the last quarter. Keybank National Association OH raised its stake in shares of Edwards Lifesciences by 0.6% during the 2nd quarter. Keybank National Association OH now owns 36,172 shares of the medical research company’s stock worth $2,829,000 after buying an additional 233 shares during the period. Finally, Assetmark Inc. raised its stake in shares of Edwards Lifesciences by 344.7% during the 2nd quarter. Assetmark Inc. now owns 2,735 shares of the medical research company’s stock worth $214,000 after buying an additional 2,120 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Stock Up 0.7%

Shares of NYSE EW opened at $86.47 on Friday. The stock has a market cap of $50.22 billion, a PE ratio of 47.25, a P/E/G ratio of 2.26 and a beta of 0.94. The company has a current ratio of 4.00, a quick ratio of 3.29 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 12-month low of $65.94 and a 12-month high of $87.89. The company has a 50-day moving average of $82.74 and a 200 day moving average of $81.25.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). The business had revenue of $1.57 billion during the quarter, compared to analysts’ expectations of $1.54 billion. Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The company’s revenue for the quarter was up 13.3% compared to the same quarter last year. During the same period last year, the business earned $0.59 earnings per share. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. As a group, sell-side analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Scott B. Ullem sold 7,700 shares of Edwards Lifesciences stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $84.47, for a total transaction of $650,419.00. Following the transaction, the chief financial officer owned 39,898 shares in the company, valued at $3,370,184.06. The trade was a 16.18% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Daniel J. Lippis sold 1,019 shares of the business’s stock in a transaction dated Friday, January 9th. The shares were sold at an average price of $85.70, for a total transaction of $87,328.30. Following the transaction, the vice president directly owned 22,002 shares in the company, valued at approximately $1,885,571.40. The trade was a 4.43% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 67,804 shares of company stock valued at $5,711,242. Insiders own 1.29% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on EW. Canaccord Genuity Group set a $87.00 price target on shares of Edwards Lifesciences and gave the company a “hold” rating in a research note on Wednesday, December 17th. Citigroup reiterated a “buy” rating and issued a $101.00 target price (up from $96.00) on shares of Edwards Lifesciences in a research report on Thursday, December 11th. Weiss Ratings reissued a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Wednesday, January 21st. Royal Bank Of Canada upped their price target on shares of Edwards Lifesciences from $95.00 to $100.00 and gave the stock an “outperform” rating in a research report on Friday, December 5th. Finally, Truist Financial set a $89.00 price target on shares of Edwards Lifesciences and gave the company a “hold” rating in a research note on Wednesday, February 11th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $96.14.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.